Investment Opportunity

Pioneering the next generation of islet cell therapy

IsleNova Cell Therapeutics is commercializing a highly differentiated autologous islet cell platform built on decades of clinical expertise and purpose-built GMP-compliant infrastructure.

The opportunity

A differentiated platform addressing significant unmet need

Our primary focus is enabling total pancreatectomy with autologous islet transplantation (TPAIT) for patients with chronic pancreatitis — a condition with significant unmet medical need and limited access to specialized processing infrastructure.

IsleNova combines a clinical services model with focused R&D, creating a strong foundation of clinical expertise and long-term growth potential in the islet cell and regenerative therapy space.

Key differentiators

What sets IsleNova apart

200+
Clinical islet isolations
Our specialists have participated in over 200 clinical islet isolation procedures — among the most experienced teams in the United States.
GMP
Purpose-built facility
A GMP-compliant cell manufacturing and cleanroom facility designed from the ground up for superior islet yield and viability — even from severely diseased tissue.
TPAIT
Focused clinical niche
Deep specialization in total pancreatectomy with autologous islet transplantation — a complex, high-value procedure with limited processing infrastructure nationwide.
R&D pipeline

Internal research programs with long-term upside

Beyond clinical services, IsleNova is actively advancing two focused internal R&D programs that extend our platform into regenerative medicine.

Islet yield optimization & predictive analytics — Ongoing studies to improve islet recovery from stressed and diseased tissue, with advanced predictive models correlating islet characteristics with long-term transplant success.
Pancreatic progenitor cell programs — Proprietary methods to harvest and characterize pancreatic progenitor cells for potential future autologous regenerative applications in diabetes and pancreatic tissue repair.
Business model

Clinical services today, regenerative platform tomorrow

Near-term revenue
Clinical islet processing services
Fee-for-service islet isolation and processing for surgical teams performing TPAIT — a defined, scalable revenue model with clear demand and limited competition.
Long-term growth
Regenerative cell therapy platform
Progenitor cell programs and islet organoid development create optionality for future therapeutic applications in chronic pancreatitis, type 1 diabetes, and type 2 diabetes.
What we are looking for

Long-term partners who share our vision

We are actively seeking long-term investors who share our vision to advance regenerative cell therapies, respect our commitment to scientific and clinical excellence, and support our primary focus on expanding access and bridging critical gaps in care for physicians and patients who currently face significant limitations to these specialized therapies.

Shared vision
Partners aligned with our mission to advance islet cell therapy and expand patient access to life-changing procedures.
Long-term orientation
Investors who understand the clinical development timeline and are committed to supporting IsleNova through launch and growth.
Scientific respect
Partners who value clinical and scientific excellence and support our commitment to regulatory compliance and patient safety.
Investor inquiry

Connect with our team

We welcome conversations with investors aligned with our mission. Please share a brief note about your interest and our team will be in touch.

IsleNova is an early-stage R&D company. This inquiry does not constitute an offer of securities. All discussions are subject to applicable securities laws.